Showing results (41-50 of 245) with videos related to

Sort By:
Pageof 25
Leukemia Research|November 4, 2008
Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemiaJohn F Marcelletti, Pratik S Multani, Jeffrey E Lancet, et al.
Leukemia Research|March 30, 2007
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalitiesAttaphol Pawarode, Sheila N J Sait, Alain Nganga, et al.
Cancer Chemotherapy and Pharmacology|April 3, 2004
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023Hans Minderman, Tracy A Brooks, Kieran L O'Loughlin, et al.
The Annals of Thoracic Surgery|July 9, 2010
Aortic valve bypass for aortic stenosis in a patient with paroxysmal nocturnal hemoglobinuriaMehrdad Ghoreishi, Maria R Baer, Ranjana Bhargava, et al.
Cytometry. Part B, Clinical Cytometry|June 2, 2006
Routine immunophenotyping in acute leukemia: Role in lineage assignment and reassignmentMisbah Qadir, Maurice Barcos, Carleton C Stewart, et al.
Anticancer Research|May 22, 2004
Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulatorsTracy A Brooks, Daniel R Kennedy, Donald J Gruol, et al.
Cancer Genetics|April 29, 2017
Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylateYing S Zou, Nicole L Hoppman, Zeba N Singh, et al.
Plos One|August 23, 2013
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsJasjeet Bhullar, Karthika Natarajan, Suneet Shukla, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 14, 2012
Drug resistance: still a daunting challenge to the successful treatment of AMLBrian C Shaffer, Jean-Pierre Gillet, Chirayu Patel, et al.
Haematologica|November 22, 2011
Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromesSheila Weiss Smith, Masayo Sato, Steven D Gore, et al.
Pageof 25